NEW YORK, March 9, 2017 /PRNewswire/ --
For today, Stock-Callers.com features the following Biotech stocks: AlnylamPharmaceuticals Inc. (NASDAQ: ALNY), INSYS Therapeutics Inc. (NASDAQ: INSY), Curis Inc. (NASDAQ: CRIS), and GenVec Inc. (NASDAQ: GNVC). These companies operate in the Healthcare sector, which ended moderately higher on Wednesday,
Cambridge, Massachusetts headquartered Alnylam Pharmaceuticals Inc.'s stock finished Wednesday's session 4.61% higher at $52.24 with a total trading volume of 932,253 shares. The Company's shares have advanced 21.46% in the past month, 26.67% over the previous three months, and 39.53% on an YTD basis. The stock is trading above its 50-day moving average by 21.51%. Furthermore, shares of Alnylam Pharma, which discovers, develops, and commercializes novel therapeutics based on RNA interference, have a Relative Strength Index (RSI) of 66.84.
On February 09th, 2017, research firm Needham reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $98 a share to $68 a share.
On March 01st, 2017, Alnylam Pharmaceuticals announced that the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) scheme for givosiran (ALN-AS1), an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias. The purpose of the PRIME initiative is to bring treatments to patients faster by enhancing the EMA's support for the development of medicines for diseases where there is an unmet medical need and where early clinical data show potential to benefit patients. The free research report on ALNY is available at:
Shares in Chandler, Arizona headquartered INSYS Therapeutics Inc. ended at $11.07, up 1.28% from the last trading session. The stock recorded a trading volume of 1.16 million shares. The Company's shares have gained 8.64% in the last one month and 20.33% since the start of this year. The stock is trading 5.60% above its 50-day moving average. Moreover, shares of INSYS Therapeutics, which develops and commercializes supportive care products, have an RSI of 48.46.
On March 02nd, 2017, Insys Therapeutics announced that the Company will release its financial results for Q4 and full year 2016 on March 16th, 2017, before the US financial markets open. Following the release of the financial results, Dr. Santosh Vetticaden, Interim CEO, and Chief Medical Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call at 10:00 a.m. ET. The complimentary report on INSY can be downloaded at:
Lexington, Massachusetts headquartered Curis Inc.'s stock ended yesterday's session 4.94% higher at $2.55. A total volume of 590,256 shares was traded, which was above their three months average volume of 513,670 shares. The Company's shares are trading 7.15% above their 200-day moving average. Additionally, shares of Curis, which engages in the discovery and development of drug candidates for the treatment of human cancers, have an RSI of 46.96.
On March 07th, 2017, Curis announced that the Company will release its Q4 and year-end 2016 financial results on March 09th, 2017, before the US financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. ET, to review its various pipeline programs, including CUDC-907, a dual HDAC/ PI3K inhibitor, CA-170, an oral small molecule antagonist of PD-L1/VISTA, and other molecules under collaboration with Aurigene, and its partnered program, Erivedge® (vismodegib) and also review its financial results as of and for Q4 and year ended December 31st, 2016. Visit us today and download our complete research report on CRIS for free at:
On Wednesday, shares in Gaithersburg, Maryland-based GenVec Inc. recorded a trading volume of 39,011 shares. The stock finished 2.60% higher at $6.71. The Company's shares have advanced 4.52% in the last one month, 126.69% in the previous three months, and 109.03% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 15.28% and 29.09%, respectively. Furthermore, shares of GenVec, which focuses on developing a pipeline of therapeutics and vaccines through its proprietary AdenoVerse gene delivery platform in the US, have an RSI of 55.71.
On January 24th, 2017, Intrexon Corporation announced that it has entered into a definitive agreement to acquire GenVec, a clinical-stage Company and pioneer in the development of AdenoVerse™ gene delivery technology. Intrexon intends to integrate and expand upon GenVec's expertise in adenoviral vectors and cGMP drug product manufacturing to enhance its broad gene transfer capabilities that encompass multiple viral and non-viral platforms. Get free access to your technical report on GNVC at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
HELLP syndrome is a rare but serious complication that affects pregnant women. If detected on time, ...
Discectomy is a surgical procedure in which a herniated (bulged) disc that compresses the nerves of ...
Parotidectomy is a surgery to remove a part of or the entire parotid salivary gland, on the side of ...View All